Yale University: COVID-19 trials

The registry lists 20 COVID-19 studies with Yale University as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 2Phase 2 5Phase 3 1No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Addressing Vaccine Acceptance in Carceral Settings Through Community EngagementRecruitingNCT05796505Not applicable
• Implementing and Evaluating a Social-Emotional Learning Program for Refugee Children During the COVID-19 PandemicCompletedNCT04931888Not applicableResults posted
• Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 SubjectsCompletedNCT04431908Results posted
• Tofacitinib for Treatment of Moderate COVID-19TerminatedNCT04415151Phase 2Results posted
• Camostat Mesylate in COVID-19 OutpatientsCompletedNCT04353284Phase 2Results posted
• The Role of Resistant Starch in COVID-19 InfectionTerminatedNCT04342689Phase 2/3Results posted
• Evaluating the Impact of Social MusicCompletedNCT06513910Not applicable
• Evaluating Social Perception DynamicsCompletedNCT06513871Not applicable
• Evaluating the Community Drum CircleCompletedNCT06513858Not applicable
• Drum Circle Synchrony Study 2c.a.CompletedNCT06513845Not applicable
• Music Mindfulness Study 2a.CompletedNCT06505226Not applicable
• Topical Antibacterial Agents for Prevention of COVID-19CompletedNCT05449392Phase 1
• Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)CompletedNCT05225064Not applicable
• Face Masks to Reduce SARS-CoV-2 Infections (COVID-19) in BangladeshWithdrawnNCT05197725Not applicable
• Yale COVID-19 Recovery StudyCompletedNCT04895189
• Respiratory Supports and COVID-19 MortalityCompletedNCT04832061
• Face Masks to Reduce COVID-19 in BangladeshCompletedNCT04630054Not applicable
• IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)TerminatedNCT04575610Phase 2
• COVID-19 Vaccine Messaging, Part 1CompletedNCT04460703Not applicable
• The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsWithdrawnNCT04435015Phase 1/2